On July 11, 2011, MicroPort announced the kick-off of the pre-approval multicenter randomized controlled clinical trial of Firebird2 drug-eluting stents in (Shanghai). The event was witnessed by dozens of renowned experts in coronary intervention as well as MicroPort's top management, including COO Philip Li Wang, CTO Qiyi Luo and CMO Bo Peng. Mr. Yimin Xu, Vice Presideng of Quality and Regulatory, chaired the meeting. The clinical trial simultaneously conducted in 17 clinical centers, in which Professor Weifeng Shen of Ruijin Hospital, Shanghai Jiaotong University School of Medicine served as principal investigator, aimed at assessing the safety and effectiveness of the stents more precisely and providing more valuable information and scientific basis for long-term application.